A Study to Evaluate ALN-2232 in Participants With Obesity

The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity

NCT Number	NCT07463846
Lead Sponsor	Alnylam Pharmaceuticals
Conditions	Obesity
Enrollment	156 participants
Start Date	2026-03-02
Primary Completion	2027-04-27 (estimated)
Study Completion	2028-03-02 (estimated)
Updated on ClinicalTrials.gov	2026-08-12